Literature DB >> 11137564

A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.

R Takahashi1, C Shimazaki, T Inaba, A Okano, M Hatsuse, A Okamoto, H Hirai, E Ashihara, M Nakagawa.   

Abstract

We examined the effect of YM529, a newly developed third-generation bisphosphonate (BP), on the growth of human myeloma cell lines using the trypan blue dye exclusion test and Alamar blue assay. BPs induced inhibition of proliferation in all cell lines dose-dependently, and YM529 had a most potent growth inhibitory effect, followed by incadronate and pamidronate. Flow cytometric analysis using annexinV and 7AAD showed that YM529 most significantly induced apoptosis of all myeloma cell lines. These observations suggested that YM529 is a potent apoptosis inducer of myeloma cells, and might have some benefit not only on the improvement of bone lesions but also on survival in some myeloma patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11137564     DOI: 10.1016/s0145-2126(00)00087-4

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  10 in total

1.  A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.

Authors:  Monica M Reinholz; Shawn P Zinnen; Amylou C Dueck; David Dingli; Gregory G Reinholz; Leslie A Jonart; Kathleen A Kitzmann; Amy K Bruzek; Vivian Negron; Abdalla K Abdalla; Bonnie K Arendt; Anthony J Croatt; Luis Sanchez-Perez; David P Sebesta; Harri Lönnberg; Toshiyuki Yoneda; Karl A Nath; Diane F Jelinek; Stephen J Russell; James N Ingle; Thomas C Spelsberg; Henry B F Hal Dixon; Alexander Karpeisky; Wilma L Lingle
Journal:  Bone       Date:  2010-03-15       Impact factor: 4.398

2.  Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma.

Authors:  Kazuho Shimura; Chihiro Shimazaki; Kyoko Taniguchi; Sonoko Akamatsu; Masashi Okamoto; Ryo Uchida; Ken-ichi Nomura; Tohru Inaba; Shigeo Horiike; Narisato Kanamura; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

3.  Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma.

Authors:  Naoya Ochiai; Noriko Yamada; Ryo Uchida; Shin-ichi Fuchida; Akira Okano; Mayumi Hatsuse; Masashi Okamoto; Eishi Ashihara; Chihiro Shimazaki
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

4.  A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.

Authors:  Helong Zhang; Seiji Yano; Toyokazu Miki; Hisatsugu Goto; Takanori Kanematsu; Hiroaki Muguruma; Hisanori Uehara; Saburo Sone
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

5.  Selective fluorescence sensing of deoxycytidine 5'-monophosphate (dCMP) employing a bis(diphenylphosphate)diimine ligand.

Authors:  Weerachai Nasomphan; Pramuan Tangboriboonrat; Srung Smanmoo
Journal:  J Fluoresc       Date:  2010-08-12       Impact factor: 2.217

6.  Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells.

Authors:  Kenichiro Yata; Takemi Otsuki; Osamu Yamada; Hideho Wada; Yoshihito Yawata; Takashi Sugihara
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

7.  Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.

Authors:  Ryuichiro Koshimune; Motoi Aoe; Shinichi Toyooka; Fumikata Hara; Mamoru Ouchida; Masaki Tokumo; Yoshifumi Sano; Hiroshi Date; Nobuyoshi Shimizu
Journal:  BMC Cancer       Date:  2007-01-12       Impact factor: 4.430

8.  The effect of alendronate on proteome of hepatocellular carcinoma cell lines.

Authors:  Amber Ilyas; Zehra Hashim; Nadia Naeem; Kanwal Haneef; Shamshad Zarina
Journal:  Int J Proteomics       Date:  2014-02-06

Review 9.  Quality of life and supportive care in multiple myeloma.

Authors:  Melda Cömert; Ajda Ersoy Güneş; Fahri Sahin; Güray Saydam
Journal:  Turk J Haematol       Date:  2013-09-05       Impact factor: 1.831

10.  Inhibition of Arenaviridae nucleoprotein exonuclease by bisphosphonate.

Authors:  Thi Hong Van Nguyen; Elsie Yekwa; Barbara Selisko; Bruno Canard; Karine Alvarez; François Ferron
Journal:  IUCrJ       Date:  2022-05-28       Impact factor: 5.588

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.